Form 4: RA Capital Affiliates Report Director Stock Option Grant in Tyra Biosciences

RA Capital Management and its affiliates, including director Jake Simson, reported the grant of 22,200 stock options in Tyra Biosciences, Inc. as part of the company's non-employee director compensation program.

Summary

• RA Capital Management, L.P., along with its affiliated funds (RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P.) and managing members (Dr. Peter Kolchinsky and Mr. Rajeev Shah), reported the acquisition of stock options in Tyra Biosciences, Inc. (TYRA).
• The transaction involved the grant of 22,200 stock options to Dr. Jake Simson, a Partner of RA Capital Management and a director on Tyra Biosciences' board.
• The options have an exercise price of $9.25 per share and an expiration date of May 28, 2035.
• Vesting occurs monthly at a rate of 1/12th of the total shares, starting from May 29, 2025. Any remaining unvested portion will vest on the date of the next annual stockholders' meeting if it occurs before the first anniversary of the grant date, contingent on Mr. Simson's continuous service.
• Mr. Simson holds these options for the benefit of RA Capital's funds and a separately managed account, with any net proceeds from exercise offsetting advisory fees owed to RA Capital Management.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects standard corporate governance practices and aligns the interests of a key director (associated with a major investor) with the company's performance. It is a routine disclosure, not indicative of major positive or negative news beyond its nature as compensation.

Positives

• The grant of stock options to a director associated with a significant institutional investor (RA Capital) aligns the director's interests with those of the company and its shareholders.
• It indicates a standard compensation practice for non-employee directors, which is a positive aspect of corporate governance.

Future Outlook

The future outlook involves the monthly vesting of the granted stock options over a 12-month period, or potentially sooner upon the next annual stockholders' meeting, contingent on the director's continued service to Tyra Biosciences.

Management Comments

• "The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program."
• "1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant."
• "In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to Jake Simson's continuous service to the Issuer through each vesting date."
• "Under Mr. Simson's arrangement with the Adviser, Mr. Simson holds the option for the benefit of the Fund, the Nexus Fund, and the Account. Mr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser."
• "RA Capital Management, L.P. (the 'Adviser') is the investment manager for RA Capital Healthcare Fund, L.P. (the 'Fund'), RA Capital Nexus Fund, L.P. (the 'Nexus Fund') and a separately managed account (the 'Account')."
• "Dr. Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors."

Industry Context

This filing represents a routine compensation event within the biotechnology and pharmaceutical industry, where non-employee directors, especially those representing significant investors like venture capital firms, are commonly compensated with equity grants to align their interests with the company's long-term performance.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard practice across publicly traded companies, particularly in the biotech sector, to incentivize long-term commitment and performance.
• The vesting schedule (monthly over a year, with potential acceleration upon an annual meeting) is a common structure for director equity awards, comparable to practices seen in companies like Moderna (MRNA) or BioNTech (BNTX) for their non-executive board members, though specific terms vary.
• The arrangement where the director holds the option for the benefit of an investment fund and offsets advisory fees is typical for representatives of venture capital or investment firms serving on portfolio company boards, ensuring the economic benefit accrues to the fund.

Corporate Governance

Related Party Transactions

• Jake Simson, a director and Partner of RA Capital Management, L.P., received stock options which he holds for the benefit of RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., and a separately managed account. Any net cash or stock received upon exercise will offset advisory fees owed by these funds to RA Capital Management, L.P.

Stakeholder Impact

• Shareholders: The equity grant aligns the interests of a director, who is also a partner at a significant investment firm (RA Capital), with the long-term performance of the company, potentially leading to more aligned decision-making.
• Employees: No direct impact mentioned, but a stable board and aligned investor interests can indirectly benefit overall company stability.
• RA Capital Funds: The options are held for the benefit of RA Capital's funds, and proceeds will offset advisory fees, directly benefiting the funds and their limited partners.

Next Steps

• Continued monthly vesting of the 22,200 stock options granted to Jake Simson, contingent on his continuous service.
• Potential acceleration of vesting upon the next annual meeting of Tyra Biosciences' stockholders if it occurs before the first anniversary of the grant date.
• Potential exercise of the options by Jake Simson (for the benefit of RA Capital funds) at the exercise price of $9.25 per share before the expiration date of May 28, 2035.

Key Dates

Keywords

Tyra Biosciences, TYRA, RA Capital Management, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology, Healthcare Investment